Candel Therapeutics (CADL)
8.50
-0.01 (0.12%)
Upcoming Events
Latest Headlines
Candel publishes phase 3 prostate cancer trial data in Lancet Oncology
June 2, 2026 8:05 AM - StreetInsider
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Loca
June 2, 2026 8:05 AM - StreetInsider
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 1, 2026 4:05 PM - StreetInsider
Candel Therapeutics Inc. (CADL) PT Raised to $9 at BofA Securities
May 18, 2026 3:22 PM - StreetInsider
Form 8-K Candel Therapeutics, For: May 15
May 15, 2026 4:19 PM - SEC Filing
Candel Therapeutics reports extended clinical benefits in phase 3 prostate cancer trial
May 15, 2026 4:05 PM - StreetInsider
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonge
May 15, 2026 4:05 PM - StreetInsider
Form SCHEDULE 13G Candel Therapeutics, Filed by: RTW INVESTMENTS, LP
May 15, 2026 8:09 AM - SEC Filing
Form 10-Q Candel Therapeutics, For: Mar 31
May 14, 2026 8:31 AM - SEC Filing
Candel Therapeutics, Inc. (CADL) Tops Q1 EPS by 20c
May 14, 2026 8:28 AM - StreetInsider
Form 8-K Candel Therapeutics, For: May 14
May 14, 2026 8:15 AM - SEC Filing
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 14, 2026 8:05 AM - Globe NewsWire
Candel Therapeutics to Present at Upcoming Investor Conferences
May 13, 2026 8:05 AM - Globe NewsWire
Candel Therapeutics schedules call on prostate cancer trial data
May 4, 2026 8:05 AM - StreetInsider
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Asso
May 4, 2026 8:05 AM - Globe NewsWire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026 4:05 PM - StreetInsider
Form ARS Candel Therapeutics, For: Dec 31
April 29, 2026 4:14 PM - SEC Filing
Form DEFA14A Candel Therapeutics,
April 29, 2026 4:12 PM - SEC Filing
Form DEF 14A Candel Therapeutics, For: Jun 23
April 29, 2026 4:07 PM - SEC Filing
Candel Therapeutics partners with EVERSANA for drug commercialization
April 29, 2026 8:05 AM - StreetInsider
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
April 29, 2026 8:05 AM - Globe NewsWire
Form SCHEDULE 13G/A Candel Therapeutics, Filed by: BlackRock, Inc.
April 27, 2026 4:14 PM - SEC Filing
Cantor Fitzgerald Starts Candel Therapeutics Inc. (CADL) at Overweight
April 20, 2026 6:14 AM - StreetInsider
Form 4 Candel Therapeutics, For: Mar 31 Filed by: Manning Paul B
April 2, 2026 5:17 PM - SEC Filing
Form 4 Candel Therapeutics, For: Mar 31 Filed by: PAPA JOSEPH C
April 2, 2026 5:11 PM - SEC Filing
Form 4 Candel Therapeutics, For: Mar 31 Filed by: Loggia Nicoletta
April 2, 2026 5:08 PM - SEC Filing
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 2, 2026 4:05 PM - StreetInsider
Form SCHEDULE 13D/A Candel Therapeutics, Filed by: Manning Paul B
March 18, 2026 4:23 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Candel Therapeutics Inc. (CADL)
March 18, 2026 7:57 AM - StreetInsider
Candel reports extended survival in lung cancer trial
March 17, 2026 8:05 AM - StreetInsider
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoin
March 17, 2026 8:05 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Candel Therapeutics Inc. (CADL)
March 13, 2026 6:10 AM - StreetInsider
Candel Therapeutics, Inc. (CADL) Misses Q4 EPS by 29c
March 12, 2026 3:57 PM - StreetInsider
Form S-8 Candel Therapeutics,
March 12, 2026 8:58 AM - SEC Filing
Form 10-K Candel Therapeutics, For: Dec 31
March 12, 2026 8:17 AM - SEC Filing
Form 8-K Candel Therapeutics, For: Mar 12
March 12, 2026 8:11 AM - SEC Filing
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
March 12, 2026 8:05 AM - StreetInsider
Full Article List
